Correlation Between ZyVersa Therapeutics and Molecular Partners
Can any of the company-specific risk be diversified away by investing in both ZyVersa Therapeutics and Molecular Partners at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ZyVersa Therapeutics and Molecular Partners into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between ZyVersa Therapeutics and Molecular Partners AG, you can compare the effects of market volatilities on ZyVersa Therapeutics and Molecular Partners and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ZyVersa Therapeutics with a short position of Molecular Partners. Check out your portfolio center. Please also check ongoing floating volatility patterns of ZyVersa Therapeutics and Molecular Partners.
Diversification Opportunities for ZyVersa Therapeutics and Molecular Partners
0.07 | Correlation Coefficient |
Significant diversification
The 3 months correlation between ZyVersa and Molecular is 0.07. Overlapping area represents the amount of risk that can be diversified away by holding ZyVersa Therapeutics and Molecular Partners AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Molecular Partners and ZyVersa Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ZyVersa Therapeutics are associated (or correlated) with Molecular Partners. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Molecular Partners has no effect on the direction of ZyVersa Therapeutics i.e., ZyVersa Therapeutics and Molecular Partners go up and down completely randomly.
Pair Corralation between ZyVersa Therapeutics and Molecular Partners
Given the investment horizon of 90 days ZyVersa Therapeutics is expected to under-perform the Molecular Partners. In addition to that, ZyVersa Therapeutics is 1.63 times more volatile than Molecular Partners AG. It trades about -0.11 of its total potential returns per unit of risk. Molecular Partners AG is currently generating about 0.02 per unit of volatility. If you would invest 663.00 in Molecular Partners AG on August 27, 2024 and sell it today you would lose (134.00) from holding Molecular Partners AG or give up 20.21% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
ZyVersa Therapeutics vs. Molecular Partners AG
Performance |
| Timeline |
| ZyVersa Therapeutics |
| Molecular Partners |
ZyVersa Therapeutics and Molecular Partners Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with ZyVersa Therapeutics and Molecular Partners
The main advantage of trading using opposite ZyVersa Therapeutics and Molecular Partners positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ZyVersa Therapeutics position performs unexpectedly, Molecular Partners can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Molecular Partners will offset losses from the drop in Molecular Partners' long position.| ZyVersa Therapeutics vs. Cns Pharmaceuticals | ZyVersa Therapeutics vs. Immix Biopharma | ZyVersa Therapeutics vs. Hepion Pharmaceuticals | ZyVersa Therapeutics vs. Zura Bio Limited |
| Molecular Partners vs. Mineralys Therapeutics, Common | Molecular Partners vs. AN2 Therapeutics | Molecular Partners vs. Pharvaris BV | Molecular Partners vs. PepGen |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Complementary Tools
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like |